Conclusion: IDH1/2-mutated B-ALL presents as Burkitt's leukemia/lymphoma-like ALL. BL-like ALL patients have higher levels of lipid metabolism with worse prognosis.Yu QianJie Jin
艾伏尼布三联方案(艾伏尼布+维奈克拉±阿扎胞苷): 2024年ASH大会公布的一项Ⅰb/Ⅱ期研究显示,新诊断(ND)AML患者接受该方案治疗,复合完全缓解率(CRc)高达94%,77%的患者达到MRD阴性;在R/R AML患者 中,CRc 达83%,MRD阴性率也高达78%...
The Scu-B incubation and detection methods were the same as those described above. Identification of the cellular targets of Scu HepG2 cell lysates were incubated with DMSO, biotin, and Scu-B at 37 °C for 2 h. Ultrafiltration to remove unbound small molecules. Then, the processed ...
b Oncoplot depicting the genetic anomalies observed in IDH1/2-Mutated or Wild type T-ALL cases of the GRAALL03/05 and FRALLE2000 studies. Genes are classified by functional groups. The right panel indicates the overall frequency of alterations per gene. c The circos plots depict the co-...
For instance, adoptive T cell therapies (ACTs) targeting CD19 have shown durable remissions in patients with refractory B cell ALL and large B cell lymphoma respectively, which has led to 1 3Vol.:(0123456789) 8 0 Journal of Neuro-Oncology (2019) 144:79–87 FDA approvals of these T cell...
T LLasho, ATefferi, APardanani, C MFinke, S RFink, A ACaron, P ADecker, R BJenkins. (2012) Differential distribution of CCDC26 glioma-risk alleles in myeloid malignancies with mutant IDH1 compared with their IDH2R140-mutated or IDH-unmutated counterparts. Leukemia 26 , 1406-1407 /...
:Fig. S1. OS of all cases (n=560) stratified by TERT (A) or 1p/19q (B) status.BothTERTpromoter mutation (A) and 1p/19q codeletion (B) were strongly associated with favorable prognosis in IDH-mutated gliomas. codel, codeleted; OS, overall survival; and 5yOS, 5-year-overall survi...
(B) Consensus clustering CDF for k = 2 to k = 10. (C) SigClust p values for all pairwise comparisons of clusters. (D) Silhouette plot for identification of core samples. Also see Figure S1. Download: Download high-res image (2MB) Download: Download full-size image Figure 2. Gene Ex...
Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) DiNardo CD1, Stein AS2, Fathi AT3,4, Montesinos P5, Odenike O6,Kantar...
All patients received ivosidenib dosed at 500 mg daily with bevacizumab doses varying from 5 to 15 mg/kg IV dosed every 2 to 3 weeks. Combination therapy was well tolerated with minimal patients experiencing toxicities requiring dose interruptions; diarrhea (n=2), creatine phosphokinase elevations...